全文获取类型
收费全文 | 2575422篇 |
免费 | 212737篇 |
国内免费 | 7681篇 |
专业分类
耳鼻咽喉 | 34507篇 |
儿科学 | 84888篇 |
妇产科学 | 72170篇 |
基础医学 | 360406篇 |
口腔科学 | 74582篇 |
临床医学 | 231186篇 |
内科学 | 512789篇 |
皮肤病学 | 58544篇 |
神经病学 | 211356篇 |
特种医学 | 104310篇 |
外国民族医学 | 720篇 |
外科学 | 395913篇 |
综合类 | 63507篇 |
现状与发展 | 5篇 |
一般理论 | 911篇 |
预防医学 | 205363篇 |
眼科学 | 57413篇 |
药学 | 187867篇 |
8篇 | |
中国医学 | 4587篇 |
肿瘤学 | 134808篇 |
出版年
2018年 | 25040篇 |
2016年 | 22788篇 |
2015年 | 26007篇 |
2014年 | 36146篇 |
2013年 | 54745篇 |
2012年 | 70204篇 |
2011年 | 74740篇 |
2010年 | 45551篇 |
2009年 | 43920篇 |
2008年 | 70792篇 |
2007年 | 75104篇 |
2006年 | 76620篇 |
2005年 | 74289篇 |
2004年 | 72172篇 |
2003年 | 69664篇 |
2002年 | 67154篇 |
2001年 | 120174篇 |
2000年 | 123859篇 |
1999年 | 104335篇 |
1998年 | 30396篇 |
1997年 | 27463篇 |
1996年 | 28107篇 |
1995年 | 27826篇 |
1994年 | 26143篇 |
1993年 | 24568篇 |
1992年 | 86965篇 |
1991年 | 84740篇 |
1990年 | 82060篇 |
1989年 | 78977篇 |
1988年 | 73465篇 |
1987年 | 72350篇 |
1986年 | 68526篇 |
1985年 | 66252篇 |
1984年 | 50215篇 |
1983年 | 42791篇 |
1982年 | 26055篇 |
1981年 | 23412篇 |
1980年 | 22065篇 |
1979年 | 46895篇 |
1978年 | 33310篇 |
1977年 | 28185篇 |
1976年 | 26223篇 |
1975年 | 27649篇 |
1974年 | 33298篇 |
1973年 | 32009篇 |
1972年 | 29481篇 |
1971年 | 27568篇 |
1970年 | 25303篇 |
1969年 | 23771篇 |
1968年 | 21861篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
I. R. Reid 《Journal of internal medicine》2015,277(6):690-706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area. 相似文献
102.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
103.
BACKGROUND Metabolic disturbances including changes in serum calcium,magnesium or phosphate(P) influence the prevalence of type 2 diabetes mellitus(DM).We assessed the importance of serum P in elderly patients with type 2 DM vs nondiabetes mellitus(non-DM) in relation to renal function.AIM To determine the association between serum P and serum glucose or insulin resistance in diabetic and non-diabetic patients.METHODS One hundred-ten subjects with a mean age of 69.02±14.3 years were enrolled.Twenty-nine of the participants had type 2 DM(26.4%).The incidence of hypertension,smoking and receiving vitamin D(vitD) derivates were recorded.The participants were classified by both estimated glomerular filtration rate(eGFR) and albuminuria categories according to the Kidney Disease Improving Global Outcomes 2012 criteria.RESULTS We divided the patients in two groups according to the P cut-off point related to DM value.A comparison between high and low P showed that body mass index30.2±6.3 vs 28.1±4.6(P=0.04),mean glucose 63.6 vs 50.2(P=0.03),uric acid 6.7±1.6 vs 6.09±1.7(P=0.05),mean intact-parathyroid hormone 68.06 vs 47.4(P=0.001),systolic blood pressure 147.4±16.7 vs 140..2±16.1(P=0.02),mean albuminuria 63.2 vs 50.6(P=0.04) and eGFR 45.6±22.1 vs 55.4±21.5(P=0.02)were significantly different.χ~2 tests showed a significant association between high P and DM,hypertension,receiving vitD,smoking and eGFR stage(χ~2=6.3,P=0.01,χ~2=3.9,P=0.03,χ~2=6.9,P=0.009,χ~2=7.04,P=0.01 and χ~2=7.36,P=0.04,respectively).The adjusted model showed that older age,female gender and increased body mass index were significant predictors of type 2 DM when entering the covariates.CONCLUSION High serum P contributes to vascular and metabolic disturbances in elderly patients with type 2 DM and renal impairment. 相似文献
104.
105.
106.
107.
R. Di Raimondo J. Sanz-Esporrn R. Pl I. Sanz-Martn F. Luengo F. Vignoletti J. Nuez Mariano Sanz 《Clinical oral investigations》2020,24(7):2351-2361
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou 相似文献
108.
109.
110.
L.‐Q. Zheng X.‐C. Han Y. Huang H.‐W. Li X.‐D. Niu J. Li 《Clinical and experimental dermatology》2015,40(3):293-297
Porocarcinoma is an unusual, locally aggressive and potentially fatal neoplasm. Several cutaneous malignancies have been described in association with porocarcinoma, including squamous cell carcinoma, basal cell carcinoma and tricholemmal carcinoma. Previous reports have indicated that the occurrence of malignant tumours in combination with porocarcinoma is extremely rare, in particular with regard to Bowen disease (BD). We report an uncommon case of porocarcinoma occurring synchronously in a single BD lesion in a 63‐year‐old woman with multiple BD lesions. The clinical and histological findings confirmed this diagnosis. 相似文献